Analysts forecast that XOMA Corp (NASDAQ:XOMA) will announce earnings of ($0.28) per share for the current quarter, Zacks reports. Two analysts have issued estimates for XOMA’s earnings, with the lowest EPS estimate coming in at ($0.41) and the highest estimate coming in at ($0.21). XOMA reported earnings per share of ($0.35) during the same quarter last year, which would suggest a positive year over year growth rate of 20%. The business is scheduled to report its next quarterly earnings results on Thursday, March 5th.
According to Zacks, analysts expect that XOMA will report full year earnings of ($0.22) per share for the current fiscal year, with EPS estimates ranging from ($0.44) to $0.03. For the next fiscal year, analysts forecast that the business will post earnings of ($1.05) per share, with EPS estimates ranging from ($1.28) to ($0.85). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for XOMA.
XOMA (NASDAQ:XOMA) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported $0.20 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.68. XOMA had a negative net margin of 10.19% and a negative return on equity of 8.93%. The firm had revenue of $8.86 million for the quarter.
XOMA has been the topic of a number of research analyst reports. TheStreet upgraded shares of XOMA from a “d+” rating to a “c” rating in a research note on Tuesday, November 12th. ValuEngine upgraded shares of XOMA from a “sell” rating to a “hold” rating in a research note on Tuesday. Zacks Investment Research upgraded shares of XOMA from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a research note on Saturday, November 9th. HC Wainwright set a $30.00 price objective on shares of XOMA and gave the company a “buy” rating in a research note on Friday, September 27th. Finally, Wedbush reiterated a “buy” rating and set a $25.00 price objective on shares of XOMA in a research note on Wednesday, August 7th. One research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $26.33.
In other news, CFO Thomas M. Burns sold 3,829 shares of the firm’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $21.96, for a total value of $84,084.84. Following the transaction, the chief financial officer now directly owns 10,384 shares in the company, valued at approximately $228,032.64. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO James R. Neal sold 4,348 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $22.00, for a total transaction of $95,656.00. Following the completion of the transaction, the chief executive officer now owns 22,017 shares in the company, valued at $484,374. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 17,459 shares of company stock worth $374,142. Insiders own 9.89% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC bought a new position in shares of XOMA in the 3rd quarter worth about $244,000. Marshall Wace LLP bought a new position in shares of XOMA in the 2nd quarter worth about $434,000. Morgan Stanley lifted its position in shares of XOMA by 2,151.6% in the 2nd quarter. Morgan Stanley now owns 23,889 shares of the biotechnology company’s stock worth $355,000 after buying an additional 22,828 shares during the last quarter. Paloma Partners Management Co acquired a new stake in shares of XOMA in the 2nd quarter worth about $510,000. Finally, Stonepine Capital Management LLC increased its holdings in shares of XOMA by 18.9% in the 2nd quarter. Stonepine Capital Management LLC now owns 270,449 shares of the biotechnology company’s stock worth $4,019,000 after acquiring an additional 43,019 shares during the period. Institutional investors own 37.20% of the company’s stock.
NASDAQ XOMA opened at $24.15 on Friday. XOMA has a 12 month low of $11.02 and a 12 month high of $26.90. The company has a debt-to-equity ratio of 1.31, a current ratio of 4.37 and a quick ratio of 4.37. The company has a market capitalization of $214.20 million, a price-to-earnings ratio of -15.19 and a beta of 1.27. The company’s fifty day moving average price is $21.75 and its two-hundred day moving average price is $18.68.
XOMA Company Profile
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.
Featured Story: What is an investor looking for in an SEC filing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.